Overview

A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.

Status:
Terminated
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and effect of TC-5214 as a single therapy in patients with major depressive disorder who exhibit inadequate response to antidepressants.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Antidepressive Agents
Duloxetine Hydrochloride